<DOC>
	<DOCNO>NCT00038610</DOCNO>
	<brief_summary>The goal clinical research study learn intensive chemotherapy , combine imatinib mesylate ( Gleevec , STI571 ) give 8 course 6 month , follow maintenance imatinib mesylate plus chemotherapy 2 year , follow imatinib mesylate indefinitely improve Philadelphia-positive acute lymphoblastic leukemia . The safety treatment also study .</brief_summary>
	<brief_title>Study Hyper-CVAD Plus Imatinib Mesylate Philadelphia-Positive Acute Lymphocytic Leukemia</brief_title>
	<detailed_description>Before treatment start , patient complete exam , include medical history documentation disease , blood , marrow test . A chest x-ray take . CT scan may take need . A bone marrow sample take large needle . An EKG MUGA ( heart function test ) perform . During treatment , patient give blood sample ( 1 tablespoon ) least twice week . A bone marrow sample repeat 2 3 week begin treatment check response . After two course chemotherapy , test do treatment repeat check response . All patient receive 2 kind chemotherapy course total 8 course . Chemotherapy course give large vein central venous catheter ( plastic tube usually place collarbone ) . Imatinib mesylate give pill chemotherapy . Course 1 start cyclophosphamide give vein 2-3 hour every 12 hour 6 dos 3 day ( Days 1,2,3 ) . Mesna give vein continuously 4 day cyclophosphamide protect bladder . Doxorubicin give vein 24 hour Day 4 . Vincristine give short infusion Days 4 11 . Dexamethasone ( steroid ) give mouth vein Days 1-4 11-14 . The imatinib mesylate give mouth breakfast large glass water daily Days 1-14 . Medicines give prevent nausea protect kidney increase amount uric acid , may release leukemia cell die . G-CSF ( growth stimulate colony factor ) give completion chemotherapy . It give allow rapid recovery normal marrow . G-CSF injected skin count recover . Treatment brain give inside spinal fluid methotrexate around Day 2 cytarabine day 7 . This do prevent leukemia develop . For patient age 60 year old , Course 1 give protective isolation room decrease risk infection ( ) . During Course 2 , patient give methotrexate infusion 24 hour first day cytarabine high dose 2 hour every 12 hour 4 dos ( Days 2 3 ) . Citrovorum factor ( leucovorin ) , antidote side effect methotrexate , give vein mouth 2-3 day ( Day 2 ) . Solumedrol ( steroid ) give vein every 12 hour 6 dos . Imatinib mesylate give mouth breakfast large glass water Days 1-14 daily , depend tolerance Course 1 . G-CSF give Course 1 . The treatment brain inside spinal fluid give Course 1 around Days 2 7 . The chemotherapy alternate hyper-CVAD plus imatinib mesylate ( Courses 1 , 3 , 5 , 7 ) methotrexate/cytarabine plus imatinib mesylate ( Courses 2 , 4 , 6 , 8 ) complete total 8 course . G-CSF give Course 1 . Anti-nausea medicine give course chemotherapy . The urine alkalized protect kidney . Antibiotics give mouth prevent infection . After 8 course , monthly maintenance chemotherapy plus imatinib mesylate give . This include daily imatinib mesylate , monthly vincristine vein , prednisone mouth 5 day every month . Maintenance chemotherapy give total 24 month , interrupt 2 period intensive chemotherapy course hyper-CVAD imatinib mesylate 6 13 month start maintenance . Imatinib mesylate continue daily tolerate indefinitely . After two course intensive chemotherapy , response treatment evaluate . If leukemia responding , therapy continue . Patients take study leukemia start get bad . During completion treatment , patient complete exam , include blood test . If need , chest X-ray CT scan do . A bone marrow sample take large needle . Patients return every 2 3 month checkup , include blood bone marrow . X-rays heart study ( MUGA ECG ) may repeat need . An Ommaya reservoir may also place surgically route treat leukemia brain prevent leukemia patient difficulty spinal treatment . An Ommaya reservoir access port insert skin scalp enters spinal fluid cavity brain . Treatment give inpatient basis ( 3 5 day ) 8 intensive course chemotherapy , indicate clinical condition . The maintenance treatment give outpatient , except course hyper-CVAD imatinib mesylate . This investigational study . The FDA approve imatinib mesylate use chronic myelogenous leukemia clinical research study . About 55 patient take part study . All MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<criteria>1 . Diagnosis previously untreated Phpositive ALL previously treat CR 12 course therapy failure one course induction chemotherapy without imatinib mesylate . 2 . Age &gt; = 15 year . Those &lt; 15 year age treat compassionate IND . 3 . Zubrod performance status &lt; = 2 ( ECOG Scale , Appendix A ) . 4 . Adequate liver function ( bilirubin &lt; = 3.0 mg/dl , unless consider due tumor ) , renal function ( creatinine &lt; = 3.0 mg/dl , unless consider due tumor ) . 5 . Adequate cardiac function assess clinically physical examination . 6 . Signed informed consent . 1 . Active serious infection control oral intravenous antibiotic . 2 . Treatment investigational antileukemic agent chemotherapy agent last 7 day study entry , unless full recovery sideeffects occur patient rapidly progressive disease judge lifethreatening . 3 . Active secondary malignancy skin cancer ( e.g . basal cell carcinoma squamous cell carcinoma ) investigator 's opinion shorten survival less 1 year . 4 . History Grade III/IV cardiac problem define New York Heart Association Criteria . 5 . Prior history treatment imatinib mesylate . 6 . Pregnancy lactate woman childbearing potential .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Lymphoblastic</keyword>
	<keyword>Acute</keyword>
	<keyword>Philadelphia-Positive</keyword>
	<keyword>Imatinib Mesylate</keyword>
	<keyword>Gleevec</keyword>
	<keyword>Glivec</keyword>
	<keyword>Imatinib</keyword>
	<keyword>STI571</keyword>
	<keyword>STI-571</keyword>
	<keyword>CGP-57148B</keyword>
	<keyword>NSC-716051</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Cytoxan速 ,</keyword>
	<keyword>Neosar速</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Adriamycin 速</keyword>
	<keyword>Rubex 速</keyword>
	<keyword>Adriamycin PFS</keyword>
	<keyword>Adriamycin RDF</keyword>
	<keyword>Vincristine</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Decadron</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>Ara-C</keyword>
	<keyword>Cytosar</keyword>
	<keyword>DepoCyt</keyword>
	<keyword>Cytosine Arabinosine Hydrochloride</keyword>
	<keyword>Mesna</keyword>
	<keyword>Mesnex</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Filgrastim</keyword>
	<keyword>Neupogen</keyword>
</DOC>